| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
AFP-464 free base targets HIF-1α (as an inhibitor with IC50 of 0.25 μM) and the aryl hydrocarbon receptor (AhR) as a potent activator. HIF-1α is a transcription factor that regulates responses to hypoxia. AhR is a ligand-activated transcription factor involved in xenobiotic metabolism. Activation of AhR by AFP-464 leads to DNA binding and apoptosis.
|
|---|---|
| ln Vitro |
AFP-464 free base is an active HIF-1α inhibitor with an IC50 of 0.25 μM. It is also a potent AhR activator. AhR activation leads to phosphorylation of p53, induction of p21Waf1/Cip1, and apoptosis. Detailed in vitro data are available.
|
| ln Vivo |
AFP-464 free base is an active HIF-1α inhibitor and AhR activator. It induces apoptosis in cancer cells.
|
| Enzyme Assay |
In vitro HIF-1α inhibition assays using cell-based reporter systems or by measuring HIF-1α protein levels and transcriptional activity. Cells are treated with AFP-464 under hypoxic conditions. AhR activation assays measure AhR binding and downstream gene expression.
|
| Cell Assay |
In vitro cell-based assays using cancer cell lines. Cells are treated with AFP-464 at various concentrations. HIF-1α activity and AhR activation are assessed. Cell viability is assessed using MTT assays. Apoptosis is assessed by measuring p53 phosphorylation, p21 expression, and caspase activity.
|
| Animal Protocol |
In vivo studies in animal models of cancer. AFP-464 is administered via various routes at doses determined from pharmacokinetic studies. Tumor growth inhibition is assessed. HIF-1α and AhR target gene expression in tumors is measured.
|
| References |
| Molecular Formula |
C22H23N4O3F3.CH4O3S
|
|---|---|
| Molecular Weight |
544.544
|
| Exact Mass |
448.172
|
| CAS # |
468719-52-0
|
| Related CAS # |
468719-52-0;1350966-83-4 (mesylate 1:1);468719-53-1 (mesylate 1:3);1523457-12-6 (HBr 1:1); 468719-51-9 (HBr 1:3);
|
| PubChem CID |
396364
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
6.378
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
32
|
| Complexity |
725
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C(NC1=CC=C(C2=CC(C3=C(N)C(F)=C(C)C(F)=C3O2)=O)C=C1F)[C@@H](N)CCCCN
|
| InChi Key |
WHWJKUICJXPKFQ-ZDUSSCGKSA-N
|
| InChi Code |
InChI=1S/C22H23F3N4O3/c1-10-18(24)20(28)17-15(30)9-16(32-21(17)19(10)25)11-5-6-14(12(23)8-11)29-22(31)13(27)4-2-3-7-26/h5-6,8-9,13H,2-4,7,26-28H2,1H3,(H,29,31)/t13-/m0/s1
|
| Chemical Name |
(2S)-2,6-diamino-N-[4-(5-amino-6,8-difluoro-7-methyl-4-oxochromen-2-yl)-2-fluorophenyl]hexanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8364 mL | 9.1821 mL | 18.3641 mL | |
| 5 mM | 0.3673 mL | 1.8364 mL | 3.6728 mL | |
| 10 mM | 0.1836 mL | 0.9182 mL | 1.8364 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
